JAMA Network
About The Study: In this cohort study of patients with breast cancer, findings suggested a potential association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use and improved outcomes among patients with breast cancer who have obesity and related metabolic conditions. These findings support further evaluation of GLP-1 RA therapy in randomized clinical trials.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
